Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis),

Slides:

Advertisements

Similar presentations

Total Knee Arthroplasty in Juvenile Rheumatoid Arthritis by David H. Palmer, Kevin J. Mulhall, Corey A. Thompson, Erik P. Severson, Edward R.G. Santos,

Advertisements

 The Juvenile Arthritis Foot Disability Index (JAFI) (Andre et al, 2004) was the primary outcome measure of the impact of JIA on the foot.  The Child.

Lyme Arthritis in Children Presenting with Joint Effusions by Matthew D. Milewski, Aristides I. Cruz, Christopher P. Miller, Ashley T. Peterson, and Brian.

?. Transition of care in patients with Juvenile Idiopathic Arthritis Philomine van Pelt, rheumatologist, trainee in paediatric rheumatology Wilhelmina.

Juvenile Idiopathic Arthritis

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

به نام خدا.

Pre (a) and post (b) contrast agent short-axis images of the third metatarsophalangeal (MTP) joint demonstrating intact capsule and plantar plate (arrows).

Selective left coronary angiography demonstrating normal left anterior descending (LAD) and left circumflex arteries and their branches (A). Selective.

Nat. Rev. Rheumatol. doi: /nrrheum

by Gillian C Hall, Louise E Tulloh, and Robert M R Tulloh

Figure 4 Antinuclear antibodies and disease activity in SLE

Mean change from baseline in disease and disability outcomes at 6 months for abatacept initiators by anti-CCP status. Mean change from baseline in disease.

Figure 2 Shared genetic loci in systemic autoimmune diseases

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Patient disposition during open-label longterm exposure period.

Benefit-risk balance. Benefit-risk balance. Predicted probabilities of developing serious infection versus predicted probabilities of achieving Boolean-based.

First-pass perfusion images through the short axis, 2-chamber views.

Percentage of patients achieving minimal disease activity (MDA): A

ACR20, ACR50, and ACR70 response rates during the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. ACR20,

Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Figure 2 Overlap of associated loci among five rheumatic diseases

Fundus photographs of the right (A) and left (B) eyes with intraretinal hemorrhages (white arrowheads) and perivascular sheathing of retinal veins (black.

Transmission map of P. jirovecii among outpatients with RA

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Percentage of patients achieving DAS28 (CRP) < 3

(A) Proposed new ANA result interpretation algorithm that includes the anti-DFS70 results. (A) Proposed new ANA result interpretation algorithm that includes.

(A) Tagged WBC scan showing WBC (arrows) localized around the right knee (asymptomatic at time of scan) and left ankle (symptomatic at time of scan). (A)

Histopathological study of the lower extremity lesions showing intravascular fibrin thrombi, medial calcification in the vessel walls, and pronounced neutrophilic.

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Percentages of (A) ACR 20, 50, and 70 responders, and (B) patients with DAS28-CRP ≤ 3.2 or < 2.6 during 5 years. Percentages of (A) ACR 20, 50, and 70.

Nat. Rev. Rheumatol. doi: /nrrheum

Updated 2016 PsA Core Domain Set.

Fluid-attenuated inversion recovery magnetic resonance imaging at the onset of the clinical investigation (A, B) and 2 months later (C, D). Fluid-attenuated.

Changes in the proportion (95% CI) of patients with (A) fatal events, (B) serious infections, (C) malignancy, (D) GI perforation, and (E) serious cardiac.

Immunoadsorption of anti-Rpp25 antibodies.

Clinical and serological evolution of the presented case.

Clinical responses over time.

Figure 1 Reproductive health in patients with rheumatic diseases

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

P75NTR and disease severity (A) in persistent oligoarticular (n=29), extended oligoarticular (n=16) and polyarticular (n=13) patients p75NTR mRNA expression.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Bold diamonds are the mean percentage of time with inactive disease during the first 12 months within the subgroup. Bold diamonds are the mean percentage.

Patient disposition, weeks 24–128.

A. A. Change from baseline in Genant-modified Sharp total score. B. Erosion score. C. Joint-space narrowing score in patients originally randomized to.

Classification system for etiology of readmission.

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

A. A. Percentages of patients with active dactylitis in ≥ 4 digits (fingers or toes) at baseline and Week 12. *p < versus baseline. Data are observed.

Changes in erosion score (A), JSN (B), and mean mTSS (C) at years 2, 6, and 10, and percentage of radiographic nonprogressors (D) over time. Changes in.

Malignancy-related events over time for all-bari-RA analysis set (IR).

Route to rheumatology and ILAR classification of A-DS and JIA, plus presenting joints involved in A-DS. Route to rheumatology and ILAR classification of.

(A) Mean (95% CI) change and (B) mean percentage (SE) change in enthesitis scores (Leeds Enthesitis Index, SPARCC Enthesitis Index, and MASES) from baseline.

Time course of levels of serum C-reactive protein (CRP; normal < 5 mg/l) and procalcitonin (PCT; normal < 0.1 ng/ml). Time course of levels of serum C-reactive.

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

All SAE* over time in 5 years.

Fluorescein angiogram of the right eye shows patchy staining of the peripheral retinal veins in the right eye, and nonperfusion of the peripheral retina.

The mTSS individual-patient change from baseline to Week 52 cumulative probability plot (observed data). The mTSS individual-patient change from baseline.

The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind.

common rheumatologic diagnoses

Changes over time of the daily prednisone dose in patients that responded to anakinra. Changes over time of the daily prednisone dose in patients that.

Anti-CarALB antibody prevalence and levels in RA and other CTD

Presentation transcript:

Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis), noninflammatory controls, and disease controls (unrelated CTD). Calprotectin levels in children with enthesis-related arthritis (ERA), arthritis controls (oligoarticular and polyarticular juvenile idiopathic arthritis), noninflammatory controls, and disease controls (unrelated CTD). MATTHEW L. STOLL et al. J Rheumatol 2011;38:2274-2275 ©2011 by The Journal of Rheumatology